Use of Antibody

Abstract

The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.

1 . A specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. 
     
     
         2 . A specific binding molecule for use as claimed in  claim 1 , wherein the specific binding molecule is raised against the human Anx-A1 protein having the amino acid sequence of SEQ ID NO:8. 
     
     
         3 . A specific binding molecule for use as claimed in  claim 1 , comprising Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which 
       
         
           
                 
                 
               
                     
                   VLCDR1 is 
                 
                     
                   (SEQ ID NO: 2) 
                 
                     
                   KASENVVTYVS 
                 
                     
                     
                 
                     
                   VLCDR2 is 
                 
                     
                   (SEQ ID NO: 3) 
                 
                     
                   GASNRYT 
                 
                     
                     
                 
                     
                   VLCDR3 is 
                 
                     
                   (SEQ ID NO: 4) 
                 
                     
                   GQGYSYPYT 
                 
                     
                     
                 
                     
                   VHCDR1 is 
                 
                     
                   (SEQ ID NO: 5) 
                 
                     
                   GYTFTNYWIG 
                 
                     
                     
                 
                     
                   VHCDR2 is 
                 
                     
                   (SEQ ID NO: 6) 
                 
                     
                   DIYPGGDYTNYNEKFKG 
                 
                     
                     
                 
                     
                   VHCDR3 is 
                 
                     
                   (SEQ ID NO: 7) 
                 
                     
                   WGLGYYFDY 
                 
             
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
       or an amino acid sequence at least 70% identical thereto. 
     
     
         4 - 14 . (canceled) 
     
     
         15 . A method for the treatment of obsessive compulsive disorder (OCD) or anxiety in a subject in need thereof, comprising administering to the subject an antibody or fragment thereof that binds human Anx-A1 having the amino acid sequence of SEQ ID NO:8, comprising Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2, and VHCDR3, wherein VLCDR1 has an amino acid sequence having up to one conservative substitution with respect to VLCDR1 of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301, and wherein each of VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3 corresponds to VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3 respectively of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301, wherein the conservative substitution in VLCDR1 with respect to the corresponding VLCDR1 of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301 is a glycine to alanine substitution. 
     
     
         16 . The method according to  claim 15 , wherein the antibody is a monoclonal antibody. 
     
     
         17 . The method according to  claim 16 , wherein the monoclonal antibody is humanized. 
     
     
         18 . The method according to  claim 15 , wherein the fragment is a Fab, F(ab′) 2  or Fv fragment or an scFv molecule. 
     
     
         19 . The method according to  claim 15 , wherein the antibody or fragment thereof comprises a polypeptide comprising SEQ ID NO:19. 
     
     
         20 . The method according to  claim 15 , wherein the antibody or fragment thereof comprises a light chain variable region and a heavy chain variable region, each of which is produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301, or a humanized antibody or fragment thereof. 
     
     
         21 . The method according to  claim 15 , wherein the specific binding molecule is present within a pharmaceutical composition. 
     
     
         22 . The method according to  claim 21 , wherein the pharmaceutical composition comprises another therapeutically active agent.